DexCom Inc. [NASDAQ: DXCM] traded at a low on 08/18/22, posting a -0.69 loss after which it closed the day’ session at $87.53. The company report on August 3, 2022 that Dexcom Announces Upcoming Conference Presentation.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 10:30am (EST).
Links to the webcasts will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference.
The results of the trading session contributed to over 2632049 shares changing hands. Over the past one week, the price volatility of DexCom Inc. stands at 2.79% while the volatility over the past one month is 4.32%.
The market cap for DXCM stock reached $33.75 billion, with 392.50 million shares outstanding and 391.05 million shares in the current float. Compared to the average trading volume of 3.47M shares, DXCM reached a trading volume of 2632049 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about DexCom Inc. [DXCM]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DXCM shares is $99.31 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DXCM stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Bernstein have made an estimate for DexCom Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 15, 2022. While these analysts kept the previous recommendation, BofA Securities raised their target price to Buy. The new note on the price target was released on March 02, 2022, representing the official price target for DexCom Inc. stock. Previously, the target price had yet another raise to $535, while BTIG Research analysts kept a Buy rating on DXCM stock.
The Average True Range (ATR) for DexCom Inc. is set at 3.71, with the Price to Sales ratio for DXCM stock in the period of the last 12 months amounting to 12.63. The Price to Book ratio for the last quarter was 15.22, with the Price to Cash per share for the same quarter was set at 7.14. Price to Free Cash Flow for DXCM in the course of the last twelve months was 156.63 with Quick ratio for the last quarter at 4.30.
How has DXCM stock performed recently?
DexCom Inc. [DXCM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.80. With this latest performance, DXCM shares gained by 6.50% in over the last four-week period, additionally sinking by -15.35% over the last 6 months – not to mention a drop of -31.29% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DXCM stock in for the last two-week period is set at 52.77, with the RSI for the last a single of trading hit 49.81, and the three-weeks RSI is set at 53.08 for DexCom Inc. [DXCM]. The present Moving Average for the last 50 days of trading for this stock 80.48, while it was recorded at 89.72 for the last single week of trading, and 107.18 for the last 200 days.
DexCom Inc. [DXCM]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and DexCom Inc. [DXCM] shares currently have an operating margin of +10.86 and a Gross Margin at +68.63. DexCom Inc.’s Net Margin is presently recorded at +6.32.
Return on Equity for this stock inclined to 7.59, with Return on Assets sitting at 3.35.
DexCom Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.30 and a Current Ratio set at 4.70.
Earnings analysis for DexCom Inc. [DXCM]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DXCM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for DexCom Inc. go to 31.40%.
Insider trade positions for DexCom Inc. [DXCM]
There are presently around $32,122 million, or 98.50% of DXCM stock, in the hands of institutional investors. The top three institutional holders of DXCM stocks are: VANGUARD GROUP INC with ownership of 43,170,869, which is approximately 2.293% of the company’s market cap and around 0.40% of the total institutional ownership; BLACKROCK INC., holding 33,434,497 shares of the stock with an approximate value of $2.93 billion in DXCM stocks shares; and BAILLIE GIFFORD & CO, currently with $1.58 billion in DXCM stock with ownership of nearly -0.646% of the company’s market capitalization.
Positions in DexCom Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 399 institutional holders increased their position in DexCom Inc. [NASDAQ:DXCM] by around 22,921,383 shares. Additionally, 439 investors decreased positions by around 31,763,249 shares, while 96 investors held positions by with 312,297,190 shares. The mentioned changes placed institutional holdings at 366,981,822 shares, according to the latest SEC report filing. DXCM stock had 81 new institutional investments in for a total of 3,102,723 shares, while 136 institutional investors sold positions of 4,835,920 shares during the same period.